In February the US health watchdog Public Citizen sent a petition to the Food and Drug Administration calling for hydroxyethyl starch intravenous solutions to be removed from the market, 5 a move supported by CHEST's lead author, John Myburgh. 6 But the global healthcare company Fresenius Kabi, which makes Voluven and was a major funder (€3.5m (£3.15m; $4m)) of the trial, has long contended that the study was improperly reported.
2 Before the trial the company took the unusual step of signing away all rights to the data, a decision it later came to regret. In 2014 it sought the assistance of The BMJ to intervene with the CHEST investigators. It then asked the Yale Open Data Access Project (YODA) to serve as an independent intermediary between the CHEST investigators and a reanalysis team to be determined, but the academic investigators rejected YODA's offer.
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The latest "independent analysis" is the first time the CHEST data have been re-examined. But the way the new analysis has been carried out raises questions about the reliability of the findings (box).
According to the new report, published as a short research letter, The BMJ contacted all eight authors for comment. It asked Myburgh and the two other researchers who authored both the original 2012 report and the reanalysis how they could describe the new report as "independent," given their involvement, but they didn't reply. Only the new report's lead author, Anushka Patel (not an author of the 2012 report), replied, but she did not answer this question.
She told
The BMJ in an email that "the aim of the re-analysis was to determine whether the primary results of the study, as presented in Table 2 of the original manuscript, were accurate. I believe the Letter is self-explanatory in this regard and we do not plan to comment further." Michael Murray, who testified at the FDA during its deliberations on hydroxyethyl starch in 2012 and has written an editorial on the need for sharing the CHEST data, 3 commented: "I am obviously pleased they re-analyzed their data, not surprised their conclusions didn't change, but disappointed that it doesn't appear that the investigators are inclined to share their data. They missed the point of my editorial." Vinay Prasad, assistant professor of medicine at Oregon Health and Science University and an adviser to The BMJ, said, "Independent re-analysis means you make the data available for someone else to analyze. Re-analyzing your own data is like standing in front of the mirror and concluding you look good whether your face is turned left or to the right."
The New England Journal of Medicine, which published the reanalysis, defended the authors' decision to call the reanalysis "independent." Jennifer Zeis of the NEJM Group told The BMJ, "The Duke Clinical Research Institute (DCRI) team analyzed the data from the CHEST study independently and without input from the CHEST authors beyond their confirmation that the The BMJ asked the Duke authors whether they were contractually permitted to publish independently of the George Institute. Karen Pieper, who led the Duke team, was unsure. "I don't have the contract available to know. It was not part of my discussion with them when we were working on the contract, because I was not interested in that being part of our responsibilities. But that said, Duke legal does put language into contracts concerning our publication rights. So it may be in there. I just don't know."
The trial data also remain the property of the George Institute, a sharp contrast to drug companies' ongoing efforts to enable wider access to clinical trial data as part of good research governance.
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As at 2016, no systematic review nor meta-analysis independent of the trial authors had examined the raw data. Regulators, too, decided to restrict the use of hydroxyethyl starch products without having seen the raw data. 
